Financings

Arbutus Biopharma Corp. closed the sale of 664,000 series A participating convertible shares to Roivant Sciences Ltd. for gross proceeds of $66.4 million.

Armo Biosciences Inc. set terms for its proposed IPO, aiming to sell 6.7 million shares at a price range of $14 to $16.

Arrowhead Pharmaceuticals Inc. priced an underwritten public offering for gross proceeds of $52.5 million.

Avexis Inc. priced an underwritten public offering for net proceeds of about $375.5 million.

Biofrontera AG filed with the SEC to raise up to $22 million in an IPO.

Exact Sciences Corp. priced its underwritten public offering of 1 percent convertible senior notes due 2025, and upsized the offering from $500 million to $600 million.

Genocea Biosciences Inc. priced concurrent underwritten public offerings for expected gross proceeds of about $53.4 million.

Intrexon Corp. priced an underwritten public offering with gross proceeds expected to be about $75 million.

Paratek Pharmaceuticals Inc. sold about 3.2 million shares of its common stock in a registered underwritten public offering for total proceeds of about $50 million.

Pherecydes Pharma SA has raised $10.3 million in a series B round.

Restorbio Inc. set terms for its proposed IPO, aiming to sell about 5.7 million shares at a price range of $14 to $16.

Solid Biosciences Inc. set terms for its proposed IPO, aiming to sell 5.9 million shares at a price range of $16 and $18.

Urogen Pharma Ltd. filed to raise up to $53.3 million in a public offering of about 1.1 million of its ordinary shares.

Vaccitech Ltd. raised £20 million (US$27.3 million) in a series A round.

Deals

Applied Biomath LLC is collaborating with Compass Therapeutics LLC for the semimechanistic pharmacokinetic and pharmacodynamic modeling of a therapy targeting solid tumors.

Avacta Group plc said its initial study with Glythera Ltd. has concluded, and the two companies have agreed to the terms of a licensing deal, which will allow them to develop drug conjugates using their combined technologies.

Beigene Ltd. gained the Asia-Pacific rights to sitravatinib from Mirati Therapeutics Inc. in a $10 million cash deal, valued at $123 million adding in additional milestones.

Cerveau Technologies Inc. signed a research agreement with the University of Pittsburgh to study an imaging agent, [18F]MK-6240, designed to identify the status and progression of neurofibrillary tangles in the brain using positron emission tomography scans.

CGT Catapult and Combigene AB said they are collaborating on a project to develop manufacturing processes for Combigene's drug candidate, CG-01, a gene therapy for the treatment of epilepsy.

Context Therapeutics Inc. made a one-time payment to Arno Therapeutics Inc. in exchange for the worldwide rights to Apristor (onapristone XR), which has been extensively studied and has established efficacy in two phase II metastatic breast cancer trials.

Desktop Genetics Ltd. acquired exclusive worldwide licensing rights for TIDE (Tracking of Indels by DEcomposition) from the Netherlands Cancer Institute.

E-Therapeutics plc disclosed agreements in artificial intelligence with Intellegens Ltd. and Biorelate Ltd.

Foundation Medicine Inc. entered a broad partnership with Pfizer Inc. focused on development, regulatory support and commercialization of companion diagnostics.

Opko Health Inc. said its subsidiary Genedx Inc. entered a research collaboration with Radboud University Medical Center to identify genes and pathways to help manage human genetic diseases.

Sandoz AG, a division of Novartis AG, inked a global partnership with Biocon Ltd. to develop, manufacture and commercialize multiple biosimilars in immunology and oncology.

Servier Canada and the New Brunswick Health Research Foundation created the $1.5 million Servier New-Brunswick Cardiac Health Improvement Fund to promote health research and innovation in the field of cardiovascular diseases in New Brunswick.

. . . And More

A new study by an international team of researchers led by Sweden's Karolinska Institute has for the first time pinpointed a mechanism for the conversion of energy-storing white fat into energy-expending brown fat, a key finding that may lead to the discovery of new diabetes and obesity treatments.

FDA advisors considering Linhaliq, an experimental Aradigm Corp. drug for a rare but severe respiratory disease in patients with chronic lung infections, declined to support a new drug application for it, citing inconsistent efficacy data and concern over the endpoint of pivotal trials.

Astrazeneca plc and Merck & Co. Inc. said the FDA approved PARP inhibitor Lynparza (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative, metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

Drug discovery in the U.K. needs to be radically reshaped, ditching "irrelevant" animal models in favor of more testing on human tissues and cells, according to a new report by the Medicines Discovery Catapult.

Glaxosmithkline plc said the FDA granted an expanded approval for Fluarix Quadrivalent (influenza vaccine) to also include children ages 6 months to 3 years of age, the minimum age of the previous indication.

Motif Bio plc received an award from the Cystic Fibrosis Foundation to fund in vitro testing that will help to advance the development of iclaprim for the treatment of lung infections in patients with cystic fibrosis.

Myriad Genetics Inc. said the FDA approved BRACAnalysis CDx for use as a companion diagnostic to identify patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation and are candidates for treatment with the PARP inhibitor Lynparza (olaparib).

Pharming Group NV said the FDA accepted the sBLA for Ruconest (recombinant C1 esterase inhibitor) as a routine prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema.